Triple
T6065084
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | SMN2 |
E135135
|
entity |
| Predicate | targetOfDrug |
P37016
|
FINISHED |
| Object | nusinersen |
E24879
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: nusinersen | Statement: [SMN2, targetOfDrug, nusinersen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: nusinersen Context triple: [SMN2, targetOfDrug, nusinersen]
-
A.
Spinraza
chosen
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
B.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
C.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
D.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
E.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: targetOfDrug Context triple: [SMN2, targetOfDrug, nusinersen]
-
A.
hasMolecularTarget
chosen
Indicates that one entity (such as a drug or compound) is directed toward, binds to, or specifically interacts with a particular molecular target (such as a protein, receptor, or gene).
-
B.
regulatoryTarget
Indicates that one entity is subject to control, influence, or governance by another entity under a regulatory or rule-based framework.
-
C.
hasPharmacologicalEffect
Indicates that one entity produces a specific pharmacological effect or action on another entity.
-
D.
hasTargetDisease
Indicates that an entity (such as a treatment, study, or intervention) is directed toward, intended to affect, or primarily concerned with a specified disease.
-
E.
hasDrugBankID
Indicates that an entity is associated with a specific identifier from the DrugBank database.
- F. None of above.
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00878d06881909ee78e88913bf890 |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c05723c91c819090b4d4672e72f9f3 |
completed | March 22, 2026, 8:54 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c11d23dca8819080702ca0f05df5dd |
completed | March 23, 2026, 10:59 a.m. |
| PD | Predicate disambiguation | batch_69c049f031408190b08b2766237c5dd0 |
completed | March 22, 2026, 7:58 p.m. |
Created at: March 22, 2026, 4:10 p.m.